6月25日，阿尔凯默斯盘中上涨6.97%，报51.395美元/股，成交额8240.75万美元。
消息面上，公司此前在Sleep 2026学术会议上公布其食欲素受体激动剂Alixorexton治疗2型发作性睡病的Vibrance-2二期研究达到双重主要终点，在第八周显著改善平均睡眠潜伏期及日间过度嗜睡，觉醒改善效果在五周期间持续维持，且未出现严重治疗相关不良事件。公司已同步启动该药物的三期临床试验。该研究是首批证实食欲素类药物对2型嗜睡症有效的大型试验之一，表明其适用患者群体有望扩大至特发性嗜睡症及ADHD等更广泛适应症。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.